www.fdanews.com/articles/186316-rubraca-approved-for-ovarian-cancer-maintenance-treatment
![Red_Approved_Stamp.gif](https://www.fdanews.com/ext/resources/test/Drug-Images4/Red_Approved_Stamp.gif?t=1578447203&width=430)
Rubraca Approved for Ovarian Cancer Maintenance Treatment
April 9, 2018
The FDA approved Clovis Oncology’s Rubraca (rucaparib) as a maintenance treatment for recurrent ovarian cancer.
The treatment is applicable for adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
Rubraca previously received regular approval as an earlier-line therapy based on positive data from the phase 3 clinical trial.